A comprehensive view of Vertex Pharmaceuticals Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.
Recent Articles
sample of recent headlines, press releases and get more..
FDA approves Vertex Pharmaceutical's Casgevy and Bluebird Bio's Lyfgenia, the first cell-based gene therapies for sickle cell disease in patients 12 years and older; both treatments use patients' own blood stem cells, a major advantage in gene therapy
Published:
December 08, 2023
by U.S. Food and Drug Administration (FDA)
|
Ask us about our Health Care Sector market view
Trending Chart
Interactive chart with headline count